Annexon, Inc.
tanruprubart
Guillain-Barré Syndrome (GBS)
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on tanruprubart for Guillain-Barré Syndrome (GBS) is in focus around Date TBD.
Primary source
· SEC 8-K
verified 16h ago
“MAA under review with EMA supported by robust data package demonstrating rapid benefit on function and disability in placebo-controlled studies and Real-World Evidence study demonstrating favorable outcomes versus current treatments, intrav”